Abstract:As a ubiquitous protein tyrosine phosphatase, SHP2 is involved in PD-1/PD-L1 mediated tumor immune escape and undergoes substantial conformational changes. Therefore, it is considered an ideal target for tumor intervention. However, the allosteric mechanisms of SHP2 binding PD-1 intracellular ITIM/ITSM phosphopeptides remain unclear, which greatly hinders the development of novel structure-based anticancer allosteric inhibitors. In this work, the open and closed structural models of SHP2 are first constructed based on this knowledge; next their motion modes are investigated via elastic network models such as the Gaussian network model (GNM), anisotropic network model (ANM) and adaptive anisotropic network model (aANM); and finally, a possible allosteric signaling pathway is proposed using a neural relational inference molecular dynamics (NRI-MD) simulation embedded with an artificial intelligence (AI) strategy. In GNM and ANM, the N-SH2, C-SH2 and PTP domains all exhibit distinct dynamics partitions, and the N-SH2/C-SH2 regions show a rigid rotation relative to PTP. According to a series of intermediate snapshots given by aANM, N-SH2 is first identified with pY223 specifically, inducing a D'E-loop to change from b-sheets to random coils, and then, C-SH2 serves as a fulcrum to drive N-SH2 to rotate 1101 completely away from the original active sites of PTP. Finally, a possible allosteric signaling-transfer path for SHP2, namely R220-R138-T108-R32, is proposed based on NRI-MD sampling. This work provides a possible allosteric mechanism of SHP2, which is helpful for the following design of novel allosteric inhibitors and is expected to be used in clinical synergies with PD-1 monoclonal antibody.

Advances in SHP2 Tunnel Allosteric Inhibitors and Bifunctional Molecules

Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application

Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies

Cross the Undruggable Barrier, the Development of SHP2 Inhibitors: from Catalytic Site Inhibitors to Allosteric Inhibitors

Recent advances in the discovery of protein tyrosine phosphatase SHP2 inhibitors

Targeting SHP2 Cryptic Allosteric Sites for Effective Cancer Therapy

Small-molecule Modulators Targeting SHP2 for Cancer Therapy

Therapeutic Potential of Targeting SHP2 in Human Developmental Disorders and Cancers

A patent review of SHP2 allosteric inhibitors (2018-present)

Strategies to overcome drug resistance using SHP2 inhibitors

Targeting SHP2 As a Promising Strategy for Cancer Immunotherapy

Overcoming Immune Checkpoint Therapy Resistance with SHP2 Inhibition in Cancer and Immune Cells: A Review of the Literature and Novel Combinatorial Approaches

Structure-based design, synthesis and biological evaluation of aminopyrazines as highly potent, selective, and cellularly active allosteric SHP2 inhibitors

Scaffold-based selective SHP2 inhibitors design using core hopping, molecular docking, biological evaluation and molecular simulation

Promising Natural Products Targeting Protein Tyrosine Phosphatase SHP2 for Cancer Therapy.

Discovery of Novel Allosteric SHP2 Inhibitor Using Pharmacophore-Based Virtual Screening, Molecular Docking, Molecular Dynamics Simulation, and Principal Component Analysis

Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders

Study on the allosteric activation mechanism of SHP2 <i>via</i> elastic network models and neural relational inference molecular dynamics simulation

Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases

Exploring the mechanism of the potent allosteric inhibitor compound2 on SHP2 WT and SHP2F285S by molecular dynamics study